Compare TMCI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | KLRS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 113.0M |
| IPO Year | 2021 | N/A |
| Metric | TMCI | KLRS |
|---|---|---|
| Price | $4.21 | $4.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.77 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.1M | 63.9K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,690,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.17 | $2.14 |
| 52 Week High | $7.78 | $11.88 |
| Indicator | TMCI | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 37.66 |
| Support Level | $3.84 | N/A |
| Resistance Level | $4.62 | $4.86 |
| Average True Range (ATR) | 0.34 | 0.49 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 33.33 | 15.81 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.